IE
RLMD icon

Israel Englander’s Relmada Therapeutics RLMD Stock Holding History

Israel Englander’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-85,000
Closed -$3.15M – 6966
2022
Q3 		$3.15M Buy
+85,000
New +$2.35M ﹤0.01% 3346
2022
Q2 		– Sell
-30,000
Closed -$810K – 7419
2022
Q1 		$810K Buy
+30,000
New +$620K ﹤0.01% 4735
2021
Q2 		– Sell
-70,000
Closed -$2.46M – 7017
2021
Q1 		$2.46M Sell
70,000
-15,000
-18% -$525K ﹤0.01% 3336
2020
Q4 		$2.73M Buy
85,000
+27,500
+48% +$945K ﹤0.01% 2981
2020
Q3 		$2.16K Buy
57,500
+7,500
+15% +$290K ﹤0.01% 2538
2020
Q2 		$2.24M Buy
+50,000
New +$2.11M ﹤0.01% 2440

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Israel Englander's RLMD Position: Q2 2026 in Review

Israel Englander reduced its Relmada Therapeutics (RLMD) stake by 40% in Q2 2026, selling an estimated $10.8M and leaving 2,361,827 shares worth $16.3M. The position accounts for 0.01% of the portfolio, ranked #1808.

Israel Englander first reported a position in RLMD in Q4 2019 and has held it in 22 quarters since. The position peaked at $27.2M in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Israel Englander held 2,361,827 shares of Relmada Therapeutics worth $16.3M as of Q2 2026.
  • Israel Englander sold 1,545,438 Relmada Therapeutics shares in Q2 2026, an estimated $10.8M.
  • Relmada Therapeutics made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1808 holding.
  • Israel Englander first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 22 quarters since.
  • Israel Englander's Relmada Therapeutics position peaked at $27.2M in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.